COMMUNIQUÉS West-GlobeNewswire

-
Genmab Publishes 2024 Annual Report
12/02/2025 -
Tanke Biosciences Corp Announces Appointment of Vincent Renz as Chief Executive Officer and Member of the Board of Directors
12/02/2025 -
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
12/02/2025 -
Board member Roland Norberg requests to resign from the Board
12/02/2025 -
Pedal for Progress with Jack Ride: Canadians Ride for Youth Mental Health
12/02/2025 -
Pédalons pour la cause : la Jack Ride mobilise le pays pour la santé mentale des jeunes
12/02/2025 -
ZymoChem Achieves Commercial-Scale Production of Key Biopolymer Ingredient For BAYSE BioSAP
12/02/2025 -
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
12/02/2025 -
New York Blood Center Enterprises Researchers Identify New Immune Response Mechanisms in Sickle Cell Disease
12/02/2025 -
Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
12/02/2025 -
Bluejay Therapeutics Appoints Mary Cromwell as Senior Vice President and Head of Technical Operations
12/02/2025 -
MAPS Announces Search for New Executive Director as it Doubles Down on Advocacy and Movement Building
12/02/2025 -
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
12/02/2025 -
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
11/02/2025 -
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
11/02/2025 -
Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025
11/02/2025 -
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
11/02/2025 -
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025
11/02/2025 -
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
11/02/2025
Pages